Organization: Fusion Pharmaceuticals Inc

Fusion raises US $25 million for cancer targeting technology

Fusion Pharmaceuticals Inc, a spin out of the Centre for Probe Development and Commercialization (CPDC), has secured US$25 million in series ‘A’ financing to support and accelerate development of new next-generation therapeutics that precisely target cancer cells.